Pay in 4 interest-free payments of $7.03 Learn more
Ships within 48 hours · Estimated delivery Sep 26 - Oct 1
4): GLP-1 products have become the dominant drivers of total revenue for both Novo Nordisk and Eli Lilly
GLP-1s thus save lives and improve long-term cardiovascular outcomes, going well beyond glucose management
If there is worsening glycemic control or failure to achieve targeted glycemic control, significant injection site reactions or allergic reactions, then other antidiabetic therapy should be considered
Lower Risk Across All Key Outcomes with GLP-1RA Compared with DPP-4 inhibitors, GLP-1RA use was associated with significantly lower risks of MACE (hazard ratio [HR]: 0.66), VTE (HR: 0.49), kidney disease progression (HR: 0.77), and all-cause mortality (HR: 0.26)
US$ 20.41
US$ 29.55
US$ 22.05
US$ 20.58
US$ 27.51
US$ 27.38
US$ 25.29
US$ 28.45
